Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
BPD at 28 days · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether corticosteroids changes disease‐specific mortality ‐ SJS and TEN (time to compared with no corticosteroids (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing ‐ return to normal *Ventilation tubes versus laser myringotomy (6 to 12 months ‐ medium‐term) Adjusted for non‐independence of within‐individual measurements Assumed ICC of 0.5 № of participants: 132 (2 RCTs) · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids showed no clear difference in hearing ‐ return to normal hearing compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.14 [0.97, 1.33]
Studies not reported
Moderate
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids may leads to lower presence/persistence of OME compared with placebo (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether oral steroids changes adverse event: systemic corticosteroid side effects compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Hearing · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids showed no clear difference in presence/persistence of OME (3 to 9 months ‐ medium‐term) № of… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.02 [0.89, 1.17]
Studies not reported
Low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Corticosteroid related adverse events · the woman
1 finding from 1 review
Mode of delivery (risk for either assisted or cesarean delivery) · pregnant women
Topical corticosteroids may leads to higher mode of delivery (risk for either assisted or cesarean delivery) compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.04
9904 participants
Low
Congenital abnormality · pregnant women
Topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.82
9433 participants
Low
Orofacial cleft · pregnant women
Topical corticosteroids may leads to higher orofacial cleft compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.12
40605 participants
Low